Gapping up
In reaction to earnings/guidance:
- FOSL +25.5%, PDD +21%, IGT +11.4%, GRWG +8.4%, XPEV +7%, HIMX +6.8%, SOL +5.7%, MFC +5.5%, HI +5.4%, EPC +5%, SSRM +3.5%, ICL +2.8%, CMPS +2.8%, NVEE +2.1%, GTBIF +2%, MTOR +2%, SDGR +2%, INMD +1.5%, DAVA +1.4%, MPLN +1%
Other news:
- FPRX +23.9% (presents first preclinical data on anti-CCR8 antibody FPA157; also stock offering)
- INBX +9.4% (announces "positive" interim results from Phase 1 trial of INBRX-109)
- CSTL +7% (presents data on DecisionDx-Melanoma and DecisionDx DiffDx™-Melanoma tests at american society of Dermatopathology 57th Virtual Annual Meeting)
- BIOX +6.8% (acquires full ownership of HB4 Soy and strategic intellectual property rights for wheat from Arcadia Biosciences (RKDA))
- BZUN +4.2% (sets New Total Order Value Record for 11.11 festival of RMB16.50 bln)
- PDLI +4% (to file a certificate of dissolution in Jan)
- CVAC +3.4% (CureVac's COVID-19 vaccine candidate, CVnCoV, suitable for standard fridge temperature logistics)
- MRNA +3.1% (completes case accrual for first interim analysis of phase 3 COVE study of mRNA-1273)
- SNPS +2.9% (acquires Moortec)
- CTRA +2.3% (to divest Cumberland Mine, Pennsylvania assets; expected to accelerate Contura's strategic exit from thermal coal production)
- JWS +2.2% (Cano Health to become publicly traded via merger with Jaws Acquisition Corp)
- QGEN +1.3% (starts commercialization of portable digital SARS-CoV-2 antigen test in the US)
- AB +1.3% (reports preliminary AUM for Oct)
Analyst comments:
- ACCO +5.5% (upgraded to Overweight from Sector Weight at KeyBanc Capital Markets)
- NOW +2.8% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- PCG +1.8% (upgraded to Outperform from Peer Perform at Wolfe Research)
- EPAM +1% (upgraded to Buy from Neutral at BofA Securities)